沙库巴曲缬沙坦在心力衰竭治疗中的应用

Application of Shakubatrivasartan in the Treatment of Heart Failure

心力衰竭是一种慢性疾病,是心脏无法泵出足够的血液为其他身体器官提供氧气,从而引发呼吸短促、疲劳和水肿等症状。目前其治疗包括病因治疗、一般治疗、药物治疗及非药物治疗等,其中血管紧张素受体脑啡肽酶抑制剂(ARNI)是当前新研发出的一类抗心衰药物,沙库巴曲缬沙坦是其代表药物,具有阻断肾素-血管紧张-醛固酮系统(RAAS)及抑制脑啡肽酶(NEP)的双重作用,新的欧美指南均推荐用于射血分数降低心力衰竭(HFrEF)的治疗。本文现就沙库巴曲缬沙坦在心力衰竭治疗中的作用机理、临床试验、药物安全性作一综述,旨在为该病的临床治疗提供参考。

Heart failure is a chronic disease in which the heart cannot pump enough blood to provide oxygen to other body organs,which can cause shortness of breath,fatigue,and edema.At present,its treatment includes etiology treatment,general treatment,drug treatment,and non-drug treatment.Among them,angiotensin receptor enkephalinase inhibitor(ARNI)is a newly developed class of anti-heart failure drugs,Shakubatrivasartanis its representative drug.It has the dual effects of blocking the renin-angiotensin-aldosterone system(RAAS)and inhibiting enkephalinase(NEP).New European and American guidelines are recommended for ejection fraction.Treatment to reduce heart failure(HFrEF).This article reviews the mechanism,clinical trials,and drug safety of Shakubatrivasartan in the treatment of heart failure in order to provide a reference for the clinical treatment of the disease.